According to the latest market report published by Credence Research, Inc. “Tardive Dyskinesia (TD) Treatment Drugs Market – Growth, Future Prospects and Competitive Analysis, 2018 – 2026” the global tardive dyskinesia (TD) treatment drugs market, expanding at a CAGR of 3.7% from 2018 to 2026.

Market Insights

Tardive dyskinesia (TD) treatment drugs market is expected to show significant market growth over the forecast period due to increase in the incidence of TD, rising number of antipsychotic prescriptions, developing healthcare infrastructure and presence of late-stage pipeline molecule. The global TD treatment drugs market is categorized on the basis of drug types such as valbenazine, deutetrabenazine and others (benzodiazepines, botulinum toxin, vitamin E, amantadine, levodopa, reserpine, dopamine-depleting agents and calcium channel blockers etc.).

Browse the full report Tardive Dyskinesia (TD) Treatment Drugs Market – Growth, Future Prospects, and Competitive Analysis, 2018 – 2026 report at

It is observed that the demand for valbenazine and deutetrabenazine is highest in the market due to the efficacy and target specificity. Valbenazine and deutetrabenazine were approved in 2017. Furthermore, being the only approved drugs on the market, these drugs will experience significant demand.

Neurocrine Biosciences announced that the recently approved, Ingrezza (valbenazine) achieved $45.8 million net sales in the third quarter in 2017. The expected launch of pipeline drug such as SNC-102 (Synchroneuron) would further drive the market growth during the forecast period. Currently, North America leads the global TD treatment drugs market due to the higher cost of therapeutics, early diagnosis of the disease and increase in the prevalence of TD. It is predicted that TD treatment drugs market in the Asia Pacific will grow significantly in coming years due to growing number of affected population and emerging healthcare infrastructure.

Market Competition Assessment:

Currently, only two drugs Valbenazine by Neurocrine Biosciences, Inc. and Deutetrabenazine by Teva Pharmaceutical Industries Ltd. are approved by US-FDA for the treatment of TD. Key players involved in R&D activities are Synchroneuron Inc. (SNC-102) and Auspex Pharmaceuticals (SD–809).

Based on drug types:

  • Valbenazine
  • Deutetrabenazine
  • Other

Tardive dyskinesia (TD) is a disorder that results in involuntary, repetitive body movements.This may include grimacing, sticking out the tongue or smacking of the lips.Additionally there may be rapid jerking movements or slow writhing movements.In about 20% of people, decreased functioning results.

Tardive dyskinesia occurs in some people as a result of long-term use of neuroleptic medications (antipsychotics, metoclopramide).These medications are usually used for mental illness, but may also be given for gastrointestinal or neurological problems.The condition typically only develops after months to years of use.The diagnosis is based on the symptoms after ruling out other potential causes.

Efforts to prevent the condition include not using or using the lowest possible dose of neuroleptics.Treatment includes stopping the neuroleptic medication if possible or switching to clozapine. Other medications such as valbenazine, tetrabenazine, or botulinum toxin may be used to lessen the symptoms.With treatment some see a resolution of symptoms while others do not. Source: Wikipedia



Please enter your comment!
Please enter your name here